Anterior Segment Company Showcase - AcuFocus at OIS@AAO 2016.
Presenter:
Al Waterhouse, President
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - Z lensHealthegy
Anterior Segment Company Showcase - Z lens at OIS@AAO 2016.
Presenter:
Paul Beer, MD, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - PowerVisionHealthegy
Anterior Segment Company Showcase - PowerVision at OIS@AAO 2016.
Presenter:
Barry Cheskin, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Richard L. Lindstrom, MD's "Thoughts on Corneal and Lens based Refractive Surgery to Enhance Near Vision in the USA: 2015" presentation from OIS@ASCRS 2015
Anterior Segment Company Showcase - Z lensHealthegy
Anterior Segment Company Showcase - Z lens at OIS@AAO 2016.
Presenter:
Paul Beer, MD, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - PowerVisionHealthegy
Anterior Segment Company Showcase - PowerVision at OIS@AAO 2016.
Presenter:
Barry Cheskin, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Richard L. Lindstrom, MD's "Thoughts on Corneal and Lens based Refractive Surgery to Enhance Near Vision in the USA: 2015" presentation from OIS@ASCRS 2015
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
DIAGNOSTICS-IMPACT ON THE PREMIUM CHANNELHealthegy
Presentation from OIS@ASCRS 2016
Richard Lindstrom, MD
Video Presentation:
https://www.youtube.com/watch?v=HekovU6ekQU&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=27
Presentation from OIS@ASCRS 2016
Mark Packer, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=CWwqmEDJOhM&index=20&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
Anterior Segment Company Showcase - Encore VisionHealthegy
Anterior Segment Company Showcase - Encore Vision at OIS@AAO 2016.
Presenter:
Bill Burns, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - IvantisHealthegy
Anterior Segment Company Showcase - Ivantis at OIS@AAO 2016.
Presenter:
Dave Van Meter, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
DIAGNOSTICS-IMPACT ON THE PREMIUM CHANNELHealthegy
Presentation from OIS@ASCRS 2016
Richard Lindstrom, MD
Video Presentation:
https://www.youtube.com/watch?v=HekovU6ekQU&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=27
Presentation from OIS@ASCRS 2016
Mark Packer, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=CWwqmEDJOhM&index=20&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
Anterior Segment Company Showcase - Encore VisionHealthegy
Anterior Segment Company Showcase - Encore Vision at OIS@AAO 2016.
Presenter:
Bill Burns, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - IvantisHealthegy
Anterior Segment Company Showcase - Ivantis at OIS@AAO 2016.
Presenter:
Dave Van Meter, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - EnvisiaHealthegy
Anterior Segment Company Showcase - Envisia at OIS@AAO 2016.
Presenter:
Benjamin Yerxa, PhD, President
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - Sensimed AGHealthegy
Anterior Segment Company Showcase - Sensimed AG at OIS@AAO 2016.
Presenter:
David Bailey, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - ReVision OpticsHealthegy
Anterior Segment Company Showcase - ReVision Optics at OIS@AAO 2016.
Presenter:
John Kilcoyne, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - LacriScienceHealthegy
Anterior Segment Company Showcase - LacriScience at OIS@AAO 2016.
Presenter:
Chris Geddes, PhD, Chief Biomedical/Plasmonics Consultant
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - TearScienceHealthegy
Anterior Segment Company Showcase - TearScience at OIS@AAO 2016.
Presenter:
Joseph Boorady, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - Novaliq GmbHHealthegy
Anterior Segment Company Showcase - Novaliq GmbH at OIS@AAO 2016.
Presenter:
Bernhard Guenther, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
Anterior Segment Company Showcase - Mynosys Cellular Devices at OIS@AAO 2016.
Presenter:
John Hendrick, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - AvedroHealthegy
Anterior Segment Company Showcase - Avedro at OIS@AAO 2016.
Presenter:
Rajesh K. Rajpal, MD, Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - PanOpticaHealthegy
Posterior Segment Company Showcase - PanOptica at OIS@AAO 2016.
Presenter:
Paul Chaney, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - Mati TherapeuticsHealthegy
Anterior Segment Company Showcase - Mati Therapeutics at OIS@AAO 2016.
Presenter:
Bob Butchofsky, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
SPOTLIGHT ON THE PREMIUM CHANNEL – AcuFocusHealthegy
Presentation from OIS@ASCRS 2016
Nick Tarantino, OD, Chief Global Clinical & Regulatory Affairs Officer
Video Presentation:
https://www.youtube.com/watch?v=Nc4T9u62rBQ&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=34
Th e use of premium IOLs requires more specifically than standard monofocal IOLs a thorough clinical and para clinical examination using modern equipments.
We will only mention micro-incision premium IOLs that are used
in our daily practice. All information regarding the characteristics of all available and especially multifocal IOLs are available in the SFO 2012 Report on presbyopia
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Myopia Management & Control Strategies.pptxRitonDeb1
Myopia is becoming epidemic burden globally. Different strategies are mentioned in this presentation based on current scientific research to combat Myopia.
High Performance IOL Power Calculation….at the push of a buttonMichael Mrochen
earSight Innovations is developing new technologies that allow accurate measurement of the eye with the ability to move cataract surgery outcomes to a new level. Cataract surgery is the most commonly performed surgery in the world with over 20 million surgeries conducted annually.
SPOTLIGHT ON THE PREMIUM CHANNEL - Abbott Medical OpticsHealthegy
Presentation from OIS@ASCRS 2016
Leonard Borrmann, Divisional VP, R&D
Video Presentation:
https://www.youtube.com/watch?v=02VOUB17Xp8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=38
The Commonwealth Fund - Putting the Patient at the Center of the Digital Univ...Healthegy
Keynote Address - Presentation by Commonwealth Fund at Digital Healthcare Innovation Summit 2016
Participant:
David Blumenthal, MD, MPP, President & CEO – Commonwealth Fund
Introduced By:
Robert Mittendorff, MD, MBA, Partner – Norwest Venture Partners
Powered by:
Healthegy
For more healthcare innovation
Visit us at Healthegy.com
StartUp Health - Private Market Perspectives - Digital Healthcare Innovation ...Healthegy
Presentation by StartUp Health at Digital Healthcare Innovation Summit 2016.
Participant:
Katya Hancock, Director of Strategic Partnerships – StartUp Health
Introduced By:
Tom Salemi, Content Director – Healthegy
Powered by:
Healthegy
For more healthcare innovation
Visit us at Healthegy.com
Masters of the Industry at OIS@AAO 2016.
Moderated By:
Jim Mazzo, Global President Ophthalmic Devices - Carl Zeiss Meditec
Participants:
Flemming Ornskov, MD, CEO - Shire
Mike Ball, CEO - Alcon
Ashley McEvoy, Company Group Chairman - Johnson & Johnson Vision Care
William J. Link, PhD, Managing Director - Versant Ventures
Ludwin Monz, PhD, President & CEO - Carl Zeiss Meditec
William Meury, Chief Commercial Officer - Allergan
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - OmerosHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.
Presenter:
Leonard M. Blum, Chief Business & Commercial Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuti...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuticals at OIS@AAO 2016.
Presenter:
David Southwell, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. Extending Depth of Focus with Small
Aperture Optics
Small aperture technology is the only corneal-based presbyopia
correcting procedure that does not rely on the use of “plus
power” in the cornea to provide near vision.
2
3. The Simple & Elegant Solution for EDOF
• Small Aperture Safety & Effectiveness:
– Extended Range of Vision: Provides a
natural range of vision from near to far
– Preserves Far Vision: Unlike monovision,
small aperture optics provides near vision
while maintaining far vision in both eyes
– Long-Lasting: Delivers long-term
performance to maintain clear near vision
over time
• Strong Science: 40+ peer-reviewed papers
• Inlay Experience: Over 30,000 patients
– Long-Term Data: >9 years
3
KAMRA® Inlay
IC-8™ IOL
4. Untapped Market Opportunity
Presbyopia Cataract
Combined ~$10 Billion Market
• Global market opportunity exceeds $5 billion1
- 40% of procedures are performed in the US
• 70+ million baby boomer population is at least
50 years old2
• Presbyopia-correcting procedures are elective
- Pricing determined by market forces, not
reimbursement rates; patients expect superior
results
• Other surgical options exist but require
significant compromise
- Sacrifice intermediate and/or distance acuity
- Loss of effect over time; glare and halo
complaints
- Irreversible
• #1 performed surgical procedure worldwide
- 3 million performed annually in the US
• Global IOL market opportunity expected to reach
$4.2 billion by 20192
- Majority of growth to be driven by premium
IOLs
• By the year 2020, nearly 14% of the global
population will be age 60 or over2
- 60+ population segment growing 3x faster than
the total global population
- Patients seeking cataract surgery at an earlier
age in developed countries
4
1 Company estimate of global cumulative addressable market for 2015-2020
2 Market Scope
5. 18 25 35
Condition by Age
45 55
Vision Correction Life Cycle
Small aperture optics improves vision for a broad spectrum
65
PRESBYOPIAAMETROPIA
KAMRA® Inlay
• Glasses
• Contact Lenses
• Monovision
• Other Inlays
75+
IC-8™ IOL
• Monofocal IOL
• Multifocal IOL
(Bifocal/Trifocal)
• EDOF IOL
• Accommodating IOL
Small Aperture Opportunity
CATARACT
• Glasses
• Contact Lenses
• LASIK/ PRK
• Phakic IOL
5
6. PRESBYOPES
MYOPES
HYPEROPES
Positioning the KAMRA® Inlay
Market Scope 2014 Refractive Surgery Market Report
• KAMRA inlay is ideal for:
– Plano presbyopes
– Myopic presbyopes
– Post-LASIK presbyopes
– Unhappy monovision
patients
6
8. Expanding the Proven Small Aperture Platform
The IC-8™ IOL
• Hydrophobic Acrylic Material
– ABBE No. 49
• Optical Design
– Single piece 360o square edge
– 6.00 mm optic diameter
– 12.50 mm overall diameter
• CE Mark Approved
• Overcomes Other PC-IOL Limitations
– Incomplete range of vision, unreliability,
glare/halo, neuroadaptation
• Commercializing in Europe, Australia
and New Zealand
• Working Toward US Approval
IOL Material
Single-piece hydrophobic acrylic
Mask
PVDF & nano-particles of carbon
1.36mm aperture
3.23mm total diameter
3200 microperforations
5 microns thick
8
Small Aperture is used to help us capture and relive moments and images in our lives over the course of our lives. It only makes sense that this same principle should be able to help us see and enjoy the world around us.
We have taken that concept and now have made available to cataract patients, expanding the the group who now can benefit from small aperture optics
High ABBE number, decreasing chromatic aberration, and true extended depth focus create outstanding image quality through the range of vision
0.27 asphericity